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The pathophysiology underlying several metabolic diseases, such as obesity, type 2 diabetes mellitus, and atherosclerosis, involves
a state of chronic low-level inﬂammation. Evidence is now emerging that the nuclear receptor Peroxisome Proliferator-Activated
Receptor (PPAR)β/δ ameliorates these pathologies partly through its anti-inﬂammatory eﬀects. PPARβ/δ activation prevents the
production of inﬂammatory cytokines by adipocytes, and it is involved in the acquisition of the anti-inﬂammatory phenotype
of macrophages inﬁltrated in adipose tissue. Furthermore, PPARβ/δ ligands prevent fatty acid-induced inﬂammation in skeletal
muscle cells, avoid the development of cardiac hypertrophy, and suppress macrophage-derived inﬂammation in atherosclerosis.
These data are promising and suggest that PPARβ/δ ligands may become a therapeutic option for preventing the inﬂammatory
basis of metabolic diseases.
1.Introduction
Over the last decade, an abundance of evidence has shown a
close link between a state of chronic low-level inﬂammation
and metabolic dysfunction. In fact, excessive nutrition
consumption or storage has the capacity to activate both
inﬂammatory and metabolic signaling networks since they
are linked and interdependent [1].
Peroxisome Proliferator-Activated Receptors (PPARs),
which are members of the nuclear receptor family, have
emerged as important regulators of metabolic and inﬂam-
matory signaling, particularly in the context of metabolic
disease [2–4]. The ability of these receptors to connect
metabolism and inﬂammation makes them interesting
targets for the treatment of metabolic diseases, such as
atherosclerosis and diabetes, through modulation of the
inﬂammatoryprocess.Here,wewillfocusonrecentadvances
in our understanding of the role of one of these PPAR
members, the PPARβ/δ, as an integrator of metabolic and
inﬂammatory signaling networks.
2. Peroxisome Proliferator-Activated
Receptors(PPARs)
PPARs are members of the nuclear receptor superfamily
of ligand-activated transcription factors that regulate the
expression of genes involved in fatty acid uptake and
oxidation, lipid metabolism, and inﬂammation [2]. To be
transcriptionally active, PPARs need to heterodimerize with
the 9-cis retinoic acid receptor (RXR) (NR2B) (Figure 1).
PPAR-RXR heterodimers bind to DNA-speciﬁc sequences
called peroxisome proliferator-response elements (PPREs),
which consist of an imperfect direct repeat of the consensus
binding site for nuclear hormone receptors (AGGTCA),
separated by one nucleotide (Direct Repeat 1, DR-1). These
sequences have been characterized within the promoter
regions of PPAR target genes. The binding occurs in such a
way that PPAR is always oriented to the DNA’s 5 -end, while
RXR is oriented to the 3 -end. In the absence of a ligand,
high-aﬃnity complexes are formed between PPAR-RXR
heterodimers and nuclear receptor corepressor proteins,2 PPAR Research
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Figure 1: Molecular mechanisms of Peroxisome Proliferator-Activated Receptors (PPARs). PPARs are ligand-activated transcription factors
that regulate gene expression through two mechanisms: transactivation and transrepression. In transactivation, PPAR-RXR heterodimers
bind to DNA-speciﬁc sequences called peroxisome proliferator-response elements (PPREs), which are located in the promoter regions of
genes involved in glucose and fatty acid metabolism. PPARs may also regulate gene expression through a DNA-independent mechanism
called transrepression. Through this mechanism, PPARs inhibit the activity of several transcription factors such as Nuclear Factor-κB, which
leads to anti-inﬂammatory eﬀects. STAT denotes signal transducers and activators of transcription, IS-GFRE is the interferon-stimulated
gene factor responsive element, and TRE is the TPA responsive element, where TPA is a phorbol ester.
which block transcriptional activation by sequestering the
heterodimer from the promoter.
In a speciﬁc cellular context, the activity of PPARs that
regulate the transcription of their target genes depends on
many factors (relative expression of the PPARs, the promoter
context of the target gene, the presence of coactivator, and
corepressor proteins, etc.). Thus, the transcriptional activity
of PPARs is modulated by coactivators and corepressors
[5]. One of the best described PPAR coactivators is PPARγ
coactivator1α(PGC-1α).Silencingmediatorforretinoicand
thyroid hormone receptor (SMRT) and the nuclear receptor
corepressor are corepressors that interact with the PPARs
in the absence of ligands [6]. Receptor-interacting protein
140 (RIP140), an important metabolic regulator, is another
ligand-dependent corepressor which interacts with PPARs.
Binding of the ligand to PPAR induces a conformational
change resulting in dissociation of corepressor proteins, so
that the PPAR-RXR heterodimer can then bind to PPREs.
Moreover, once activated by the ligand, the heterodimer
recruits coactivator proteins that promote the initiation of
transcription [4]. As a result of these changes in transcrip-
tional activity, binding of ligands to the receptor leads to
changes in the expression level of mRNAs encoded by PPAR
target genes.
Finally, PPAR activity is also regulated at the posttran-
scriptional level by phosphorylation, ubiquitinylation, and
sumoylation (for a detailed review, see [5]).
However, the regulation of gene transcription by PPARs
extends beyond their ability to transactivate speciﬁc tar-
get genes. PPARs also regulate gene expression indepen-
dently of binding to PPREs. They cross-talk with other
types of transcription factors and inﬂuence their function
without binding to DNA, through a mechanism termed
receptor-dependent trans-repression [7]. Most of the anti-
inﬂammatory eﬀects of PPARs can probably be explained
in this way [8, 9]. Through this DNA-binding indepen-
dent mechanism, PPARs suppress the activities of several
transcription factors, including nuclear factor κB( N F -
κB), activator protein 1 (AP-1), signal transducers and
activators of transcription (STATs), and the nuclear factor
of activated T cells (NFAT). There are three main tran-
srepression mechanisms by which ligand-activated PPAR-
RXR complexes negatively regulate the activities of other
transcription factors. First, transrepression may result from
competition for limited amounts of shared coactivators.
Under conditions in which the levels of speciﬁc coactivators
are rate-limiting, activation of PPAR may suppress the
activity of other transcription factors that use the same
coactivators [10, 11]. In the second mechanism, activated
PPAR-RXRheterodimersarebelievedtoactthroughphysical
interaction with other transcription factors (e.g., AP-1,
NF-κB, NFAT, or STATs). This association prevents the
transcription factor from binding to its response element
and thereby inhibits its ability to induce gene transcription
[12]. The third transrepression mechanism relies on the
ability of activated PPAR-RXR heterodimers to inhibit
the phosphorylation and activation of certain members
of the mitogen-activated protein kinase (MAPK) cascade
[13], which prevents activation of downstream transcription
factors.
The PPAR family consists of three members, PPARα
(NR1C1 according to the uniﬁed nomenclature system for
the nuclear receptor superfamily), PPARβ/δ (NR1C2) and
PPARγ (NR1C3) [14]. PPARα was the ﬁrst PPAR to be iden-
tiﬁed and is the molecular target of the ﬁbrate hypolipidemic
class of drugs. This PPAR isotype is expressed primarily
in tissues that have a high level of fatty acid catabolism,
such as liver, brown fat, kidney, heart, and skeletal muscle
[15]. PPARγ has a restricted pattern of expression, mainly
in white and brown adipose tissue and colon, and is also
expressed in macrophages. Other tissues, such as skeletal
muscle and heart, contain only limited amounts. PPARβ/δ
is ubiquitously expressed and for this reason it was initially
considered a “housekeeping gene” [16]. However, studies
with knockout mice [17–19] and the development of speciﬁc
and high-aﬃnity ligands for this receptor have shown that
PPARβ/δ is a potential molecular target to prevent or treat
several metabolic disorders.PPAR Research 3
Natural ligands for the PPARs are believed to include
native and modiﬁed polyunsaturated fatty acids and
eicosanoids. Since the discovery of PPARs, a number of
synthetic ligands for these receptors have been identiﬁed
[20]. Thus, ﬁbrates activate PPARα, whereas the antidiabetic
drugs thiazolidinediones activate the γ isotype [21, 22].
3. PPARβ/δ-SpeciﬁcFeaturesandLigands
The crystal structure of the ligand-binding domain of the
PPARβ/δ isotype, which was ﬁrst cloned in Xenopus laevis
[23], revealed an exceptionally large pocket of approximately
1300 ˚ A3. This pocket is similar to that of PPARγ,b u tm u c h
larger than the pockets of other nuclear receptors [24, 25].
This may partially explain the great variety of natural and
synthetic ligands that bind to and activate this nuclear
receptor. Saturated (14 to 18 carbons) and polyunsaturated
(20 carbons in length) fatty acids have aﬃnities for PPARβ/δ
in the low micromolar range [25–28]. In addition, all-
trans-retinoic acid (vitamin A) [29] and fatty acids derived
from very low density lipoprotein (VLDL) [30]c a na c t i v a t e
PPARβ/δ. Finally, the number of experimental studies on
the role of PPARβ/δ in cellular processes increased greatly
as a result of the availability of several synthetic ligands
(includingGW501516,GW0742,andL-165041)thatactivate
PPARβ/δ at low concentrations both in vivo and in vitro
and have high selectivity over other PPAR isotypes [31].
The EC50 for these compounds, which were assessed with
recombinant human PPARβ/δ, were 1.0nM for GW0742,
1.1nM for GW501516, and 50nM for L-165041 [31, 32].
Recently, the ﬁrst PPARβ/δ synthetic antagonist (GSK0660)
has been identiﬁed [33].
4. PPARβ/δ, Inﬂammation, andAdipose Tissue
The expansion of adipose tissue, mainly in the form of
visceral obesity, may contribute to enhanced inﬂammation
in this tissue through several processes. First, macrophages
can inﬁltrate in adipose tissue, which contributes to the
overproduction of inﬂammatory cytokines, such as tumor
necrosis factor α (TNF-α) and interleukin 6 (IL-6) [34–36].
Indeed, the inﬁltration of macrophages into adipose tissue
correlates with the degree of insulin resistance [34]. Second,
as visceral fat (which is very sensitive to lipolytic stimuli)
increases, so does the rate of lipolysis. This leads to increased
free fatty acid (FFA) mobilization and elevated levels of cir-
culating FFA. Several studies have consistently demonstrated
that elevations of plasma FFA produce insulin resistance
in diabetic patients and in nondiabetic subjects [37–39].
SaturatedFFAarepotentactivatorsoftheToll-likereceptor-4
(TLR4) [40] and recent evidence suggests that inﬂammatory
processes induced by obesity and a high-fat diet cause
systemic insulin resistance via a mechanism involving this
receptor [41]. TLR-4 is expressed in virtually all human cells
and binds a wide spectrum of exogenous and endogenous
ligands, including bacterial lipopolysaccharide (LPS) [42].
In the presence of LPS, the TLR4 complex (including CD-
14 and an accessory protein, MD-2) recruits the adaptor
protein, myeloid diﬀerentiation factor-88 (MyD88), which
in turn recruits interleukin-1 receptor-associated kinase
(IRAK). This leads to the activation of the proinﬂamma-
tory transcription factor NF-κB[ 43] and the subsequent
enhanced expression of several inﬂammatory mediators
(including IL-6 and monocyte chemoattractant protein-1
[MCP-1]). These observations indicate that saturated FFA
derived from adipocytes and from high-fat diets activate
TLR and the inﬂammatory pathway in adipocytes and
macrophages, which contribute to the synthesis and pro-
duction of cytokines such as TNF-α [44]. In addition,
high-fat diets raise plasma LPS to a concentration that
is high enough to increase body weight, fasting glycemia,
and inﬂammation [45]. Furthermore, LPS receptor-deleted
mice (CD14 mutants) are hypersensitive to insulin, and the
development of insulin resistance, obesity, and diabetes in
this animal model is delayed in response to a high-fat diet
[45]. Experiments performed in our laboratory have demon-
strated that the PPARβ/δ agonist GW501516 inhibits LPS-
inducedcytokineexpressionandsecretionbypreventingNF-
κB activation in adipocytes [46]. Of note, NF-κBa c t i v a t i o n
by LPS requires mitogen-activated protein kinase (MAPK)-
extracellular signal-related kinase (ERK)1/2 (MEK1/2) acti-
vation, since inhibition of this pathway reduces LPS-induced
cytokine production in adipocytes [47]. In agreement with
this role of ERK1/2 in inﬂammation in adipocytes, the
expression of proinﬂammatory cytokines in these cells drops
when they are exposed to LPS in the presence of the MAPK
pathway inhibitor U0126. Interestingly, in white adipose tis-
sue from PPARβ/δ- n u l lm i c ew eo b s e r v e di n c r e a s e dE R K 1 / 2
phosphorylation and NF-κB activity and higher expression
of IL-6 compared with wild-type mice [46]. Moreover, in
the white adipose tissue of a genetic model of obesity and
diabetes, the Zucker diabetic fatty (ZDF) rat, the reduction
in the expression of PPARβ/δ correlated with an increase in
ERK1/2 phosphorylation and NF-κB activity. These ﬁndings
suggest that PPARβ/δ activation prevents LPS-induced NF-
κB activation via ERK1/2, thereby reducing the production
of proinﬂammatory cytokines involved in the development
of insulin resistance.
In addition, PPARβ/δ is involved in the phenotypic
switch of adipose tissue-resident macrophages that modu-
lates insulin sensitivity [48]. Thus, it has been suggested
that macrophages inﬁltrated in adipose tissue from lean
animals show an alternatively activated M2 phenotype [49]
that is induced by Th2 cytokines, such as IL-4 and IL-
13. These macrophages produce IL-10, a cytokine that
inhibits inﬂammation [50]. In contrast, high-fat diets lead
to inﬁltration of macrophages that show markers of classic
activation by Th1 cytokines, such as TNF-α and IL-1β. These
M1 phenotypic macrophages produce proinﬂammatory
cytokines that lead to metabolic disturbances. In inﬁltrated
macrophages in adipose tissue and liver, the signaling of
Th2 cytokines is transduced by PPARβ/δ through a signal
transducer and activator of transcription 6 (STAT6) binding
site on its promoter, which induces alternative activation.
The subsequent switch to the M2 phenotype prevents the
inﬂammation caused by inﬂammatory mediators, such as
FFA, in adipose tissue and liver. In agreement with this4 PPAR Research
model, myeloid-speciﬁc PPARβ/δ−/− mice show adipocyte
disfunction, insulin resistance, and hepatosteatosis [48].
5. PPARβ/δ, Inﬂammation, andInsulin
Resistance inSkeletalMuscleCells
FFAs may cause insulin resistance in skeletal muscle through
several mechanisms, including eﬀects on metabolism [51,
52], signaling [53, 54], and mitochondrial function [55,
56]. In addition, FFAs activate proinﬂammatory pathways,
linking the development of this pathology to a chronic
low-grade systemic inﬂammatory response [57]. In addition
to FFA-induced inﬂammation through TLR, an additional
pathway leads to FFA-mediated inﬂammation. This pathway
involves intracellular accumulation of fatty acid derivatives.
Once fatty acids are taken up by skeletal muscle cells they are
either stored as fatty acid derivatives or undergo β-oxidation
in the mitochondria. In the presence of high plasma FFA,
fatty acid ﬂux in skeletal muscle cells exceeds its oxidation,
which leads to the accumulation of fatty acid derivatives,
such as diacylglycerol (DAG), which can then activate a
number of diﬀerent serine kinases that negatively regulate
insulin action. Thus, DAG is a potent allosteric activator
of protein kinase Cθ (PKCθ), which is the most abundant
PKC isoform in skeletal muscle [58–60]. This PKC isoform
inhibits the action of insulin by phosphorylating certain ser-
ine residues on insulin receptor substrate 1 (IRS1), including
Ser307 in the rodent IRS-1 protein (reviewed in [61]). This
phosphorylation impairs insulin-receptor signaling through
several distinct mechanisms [62]. PKCθ also impairs insulin
sensitivity by activating another serine kinase, IκB kinase
β (IKKβ)[ 63]. In addition to phosphorylating IRS-1 in
Ser307,I K K β phosphorylates IκB. Thus, it activates the
proinﬂammatory transcription factor NF-κB, which has
been linked to fatty acid-induced impairment of insulin
action in skeletal muscle in rodents [64, 65]. Once activated,
NF-κB regulates the expression of multiple inﬂammatory
mediators, including IL-6. This cytokine correlates strongly
with insulin resistance and type 2 diabetes [66–68] and its
plasma levels are 2-3 times higher in patients with obesity
and type 2 diabetes than in lean control subjects [67].
Accumulation of fatty acid derivatives can be attenuated
by mitochondrial β-oxidation. The rate-limiting step for β-
oxidation of long-chain fatty acids is their transport into
mitochondria via carnitine palmitoyltransferase-1 (CPT-
1). The activity of this enzyme is inhibited by malonyl-
CoA, the product of acetyl-CoA carboxylase, which, in
turn, is inhibited by the AMP-activated protein kinase
(AMPK). This kinase is a metabolic sensor that detects
low ATP levels and increases oxidative metabolism [69], by
reducing the levels of malonyl-CoA. Interestingly, activation
of fatty acid oxidation by overexpressing CPT-1 in cultured
skeletal muscle cells [70] and in mouse skeletal muscle
[71] improves lipid-induced insulin resistance. Hence, this
approach may provide a valid therapeutic strategy to prevent
this pathology. Activation of PPARβ/δ by its ligands (includ-
ing GW501516) enhances fatty acid catabolism in adipose
tissue and skeletal muscle, thereby delaying weight gain (for
ar e v i e w ,s e e[ 72]). This increase in fatty acid oxidation in
human skeletal muscle cells following PPARβ/δ activation
by GW501516 is dependent on both PPARβ/δ and AMPK
[73]. AMPK is activated by GW501516 by modulating the
A TP:AMPratio[73]. Despite these data, little information
was available on whether the increase in fatty acid oxidation
attained after PPARβ/δ activation prevented fatty acid-
induced inﬂammation and insulin resistance in skeletal
muscle cells. However, we have recently reported that the
PPARβ/δ ligand GW501516 prevented palmitate-induced
inﬂammation and insulin resistance in skeletal muscle cells
[74]. Treatment with GW501516 enhanced the expression
of two-well known PPARβ/δ-target genes involved in fatty
acid oxidation, CPT-1 and pyruvate dehydrogenase kinase
4 (PDK-4), and increased the phosphorylation of AMPK
(Figure 2). This prevented the reduction in fatty acid oxi-
dation caused by palmitate exposure. In agreement with
these changes, GW501516 treatment reversed the increase
in DAG and PKCθ activation caused by palmitate. These
eﬀects were abolished in the presence of the CPT-1 inhibitor
etomoxir, thereby implicating increased fatty acid oxidation
in the changes. Consistent with these ﬁndings, PPARβ/δ
activation by GW501516 blocked palmitate-induced NF-κB
DNA-bindingactivity.Likewise,drugtreatmentinhibitedthe
increase in IL-6 expression caused by palmitate in C2C12
myotubesandhumanskeletalmusclecells,aswellasthepro-
teinsecretionofthiscytokine.Overall,theseﬁndingsindicate
thatPPARβ/δ attenuatesfattyacid-inducedNF-κBactivation
and the subsequent development of insulin resistance in
skeletal muscle cells by reducing DAG accumulation. To our
knowledge no studies have assessed whether this mechanism
operates in humans. However, since GW501516 increases
CPT-1 expression and palmitate oxidation in human skeletal
muscle [75, 76], this possibility merits further exploration.
6. PPARβ/δ,I nﬂ am m atio n,andH eartF unc tio n
The constant pumping of the heart requires a high energy
supply, which is mainly met by fatty acids and glucose. The
oxidation of fatty acids and glucose covers 65% and 30%
of the energy demand of the adult heart, respectively [77].
The heart, in contrast to other tissues such as the brain,
adapts its metabolism to substrate availability. For example,
an increase in glucose utilization and a decrease in fatty
acid oxidation is observed during cardiac hypertrophy and
congestive heart failure [78–80]. PPARβ/δ. is involved in the
control of fatty acid oxidation in heart, which is similar
to its role in skeletal muscle. We have reported that the
levels of both PPARα and PPARβ/δ are reduced in pressure-
overload cardiac hypertrophy [81]. Therefore, the fall in the
expression of both PPAR subtypes during the development
of cardiac hypertrophy may be necessary to downregulate
the expression of genes involved in fatty acid metabolism.
Interestingly, the changes that cardiac hypertrophy causes in
the expression of genes involved in fatty acid metabolism
were not observed when NF-κB activity was inhibited
[82]. These data pointed to the involvement of NF-κBi n
the changes. Therefore, we evaluated whether mechanismsPPAR Research 5
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Figure 2: Potential mechanism of action involved in the reduction of insulin resistance and inﬂammation in skeletal muscle cells
following PPARβ/δ activation by GW501516. ACC-2, acetyl-CoA carboxylase 2; AMPK, AMP-activated protein kinase; CPT-1, carnitine
palmitoyltransferase-1; DAG, diacylglycerol; IKKβ,I κB kinase β; IL-6, interleukin 6; IRS-1, Insulin Receptor Substrate 1; NF-κB, Nuclear
Factor-κB; PDK-4, pyruvate dehydrogenase kinase 4; PKCθ, protein kinase Cθ.
such as protein-protein interaction between NF-κBa n d
PPAR contribute to the changes in the expression of genes
involved in cardiac fatty acid metabolism, in addition to
the reported reduction in the expression of PPARs during
cardiac hypertrophy [83]. Using both in vitro and in vivo
models of cardiac hypertrophy, we studied the contribution
of NF-κB activation to the downregulation of fatty acid
oxidation during this process. Stimulation of rat neonatal
cardiomyocytes with phenylephrine (PE), which leads to
NF-κBa c t i v a t i o n[ 84], caused cardiac hypertrophy that
was accompanied by a fall in the expression of PDK-4
and palmitate oxidation. Furthermore, the reduction in the
expression of PDK-4 and fatty acid oxidation observed in
PE-stimulated rat neonatal cardiomyocytes was restored by
NF-κB inhibitors. These ﬁndings and additional studies
[85] pointed to the involvement of NF-κB in the down-
regulation of fatty acid oxidation during the development
of cardiac hypertrophy. In agreement with this idea, a
study demonstrated that cardiomyocyte-restricted PPARβ/δ
deletion in heart of mice reduced myocardial fatty acid
oxidation and the mRNA expression of genes involved in
this process, such as PDK-4, and led to cardiomyopathy
[86]. The mechanism by which activation of NF-κB results
in reduced expression of PPARβ/δ target genes seems to
involve reduced interaction of this PPAR subtype with its
cis-regulatory element, since NF-κB activation caused a
dramatic reduction in the binding of PPARβ/δ protein to
the PPRE probe. This reduction was partially reversed by
co-incubation of the cells with NF-κB inhibitors, which
conﬁrms the involvement of this transcription factor in the
changes observed. Therefore, the reduced binding activity
of PPARβ/δ seems to be related to the activation of NF-
κB in cardiac cells. However, the mechanism by which NF-
κB activation prevented the interaction of PPARβ/δ with
its response element still had to be established. NF-κBi s
present in the cytoplasm as an inactive heterodimer that
consists mostly of the p50 and p65 subunits. However, after
activation, this heterodimer translocates to the nucleus and
regulates the expression of genes involved in inﬂammatory
and immune processes. Our results indicated that once the
p65 subunit of NF-κB reaches the nucleus it interacts with
PPARβ/δ. This association prevents PPARβ/δ from binding
to its response element, and thereby inhibits its ability to
induce gene transcription, which leads to a reduction in
the expression of PDK-4. In a recent study it has also
been reported that PPARβ/δ ligands and overexpression of
this nuclear receptor suppressed myocardial inﬂammatory
responses, such as the lipopolysaccharide-mediated pro-
duction of TNFα. This had beneﬁcial eﬀects on animals
that had undergone ischemia/reperfusion injury or cardiac
hypertrophy [87].
7. PPARβ/δ, Inﬂammation, and Atherosclerosis
There is a strong relationship between circulating lipopro-
teins and atherosclerosis, since modiﬁed LDL-cholesterol
particles are taken up by monocyte-derived macrophages,6 PPAR Research
which leads to the formation of what are known as foam cells
in the arterial intimal wall. Furthermore, these macrophages
contribute to the inﬂammatory reaction by the production
and secretion of numerous proinﬂammatory cytokines [88].
Treatment of obese rhesus monkeys, which are a model
for human obesity and its associated metabolic disorders,
with the PPARβ/δ agonist GW501516 increased HDL-
cholesterol (79%), and decreased triglycerides (56%), LDL-
cholesterol (29%), and fasting insulin levels (48%) [22].
A decrease in proatherogenic small dense LDL was also
observed in treated animals [89]. It has been suggested
that the increase in HDL-cholesterol levels after PPARβ/δ
treatment is caused by enhanced cholesterol eﬄux, which
is stimulated by higher expression of the reverse cholesterol
transporter ATP-binding cassette A1 (ABCA1) in several
tissues, including human and mouse macrophages and
intestinal cells and ﬁbroblasts [90, 91]. Apart from these
beneﬁcial eﬀects of PPARβ/δ activation on HDL levels,
treatment with this compound also increased HDL particle
size in primates [92]. This eﬀect is thought to be protective
against the progression of coronary artery disease in humans
[93]. In addition, PPARβ/δ activation reduces cholesterol
absorption through a mechanism that may at least partly
involve reduced intestinal expression of Niemann-Pick C1-
like 1 (Npc1l1), which is the proposed target for ezetimibe,
an inhibitor of cholesterol absorption [91]. Furthermore,
deletion of PPARβ/δ in mice led to enhanced LDL and
triglyceride levels [94]. The administration of a PPARβ/δ
agonist to obese and diabetic db/db mice slightly increased
HDL particles, without aﬀecting triglyceride levels [90].
In a shorter treatment with GW501516, a reduction in
plasma free fatty acids and triglyceride levels was observed
in db/db mice, but not in mice exposed to a high-fat diet
[95]. In humans, there are conﬂicting reports on whether
PPARβ/δ polymorphisms are associated with changes in
plasma lipoproteins. Thus, while some authors found an
association between a PPARβ/δ polymorphism and plasma
lipids [96], this was not conﬁrmed by others [97]. These
discrepancies could be caused by diﬀerences in sex or the
inﬂuence of gene-environment interactions, since a recent
study reported that the association between the PPARβ/δ-
87T>C polymorphism and plasma HDL-cholesterol might
be sex-speciﬁc, with women showing a stronger association.
This association was only observed in subjects consuming a
low-fat diet [98]. The authors concluded that the presence
of the PPARβ/δ-87T>C polymorphism, which may result in
enhanced PPARβ/δ activity, is associated with lower risk of
suﬀering from metabolic syndrome and that this association
depends on the amount of fat consumed. In summary, the
ﬁndingsthatarecurrentlyavailableontheeﬀectsofPPARβ/δ
activation on lipoprotein metabolism are so promising that
PPARβ/δ drugs are now in clinical trials for the treatment of
human dyslipidemia.
During the development of atherosclerosis, macrophages
contribute to inﬂammation by producing and secret-
ing numerous proinﬂammatory cytokines [99]. Activated
macrophages express the three PPAR isotypes. Whereas
the roles of the PPARα and γ isotypes in macrophage
cholesterol homeostasis are well established, the role of
PPARβ/δ remains controversial. Oliver et al. [100] showed
that treatment of THP-1 human monocytes with the
PPARβ/δ ligand GW501516 enhanced the expression of the
reverse cholesterol transporter ABCA1 and induced apoA1-
speciﬁc cholesterol eﬄux. Opposite ﬁndings were reported
by Vosper et al. [101]. They found that treatment with a
diﬀerent PPARβ/δ ligand promoted lipid accumulation in
human macrophages (THP-1) exposed to oxidized LDL by
increasing the expression of the class A and B scavenger
receptors (SR-A and CD-36) and the lipid storage-related
genes aP2 and adipophilin [101]. Finally, two studies showed
that cholesterol eﬄux or accumulation was not aﬀected
by PPARβ/δ depletion or by PPARβ/δ ligands in murine
macrophages [102, 103]. Collectively, these ﬁndings suggest
thatPPARβ/δ doesnotaﬀectcholesterolmetabolisminmice.
However, additional studies are needed to establish the role
of this nuclear receptor in human macrophage cholesterol
metabolism.
It is accepted that inﬂammation links dyslipidemia
to atherosclerotic plaque formation [104]. Several stud-
ies have described a role for PPARβ/δ in inﬂammation
in atherosclerosis. For instance, atherosclerosis-prone LDL
receptor-null mice transplanted with bone marrow from
PPARβ/δ-deﬁcient mice and fed a high-cholesterol diet
showed smaller vascular lesions (50% reduction) than
wild-type recipient controls [102], whereas no signiﬁcant
diﬀerences between the two groups were found for plasma
cholesterol levels. However, PPARβ/δ-null macrophages had
lower expression of the inﬂammation markers MCP-1,
interleukin 1β (IL-1β), and metalloproteinase 9 (MMP-
9) [102]. In contrast, PPARβ/δ ligands suppressed the
expression of these inﬂammation markers in wild-type
macrophages. These ﬁndings led to the suggestion that
PPARβ/δ regulates an inﬂammatory switch by binding or
releasing the anti-inﬂammatory transcriptional suppressor
protein B cell lymphoma-6 (BCL-6) [72, 102]. In the absence
of the ligand, PPARβ/δ sequesters BCL-6, which leads to
inﬂammation. However, in the presence of the ligand,
PPARβ/δ releases BCL-6, which then represses inﬂammatory
gene expression. Similarly, deletion of PPARβ/δ also releases
BCL-6, which has anti-inﬂammatory eﬀects. Therefore, this
mechanism may explain how both PPARβ/δ activation and
the deletion of this nuclear receptor result in a similar reduc-
tion of inﬂammation. Whether additional mechanisms may
contribute to the anti-inﬂammatory eﬀect of the PPARβ/δ
isotype remains to be studied. It should be noted that part of
the anti-inﬂammatory eﬀects of PPARγ agonists used at high
concentrations in macrophages has been attributed to the
activation of PPARβ/δ [105], since at high concentrations,
PPARγ ligands may activate both PPAR isotypes. Although
these ﬁndings indicate that PPARβ/δ activation may be
beneﬁcial in the treatment of atherosclerosis, in vivo studies
are contradictory. Thus, Li et al. [103]r e p o r t e dn oe ﬀect
of the PPARβ/δ agonist GW0742 on atherosclerotic lesion
size in male LDL
−/− mice fed an atherogenic diet (1.25%
cholesterol). In contrast, Graham et al. [106] reported that
administration of GW0742 to female LDL
−/− mice fed an
atherogenic diet (0.25% cholesterol) reduced atheroscle-
rosis by 30%. Diﬀerences between these two studiesPPAR Research 7
(sex, cholesterol supplementation, or drug doses) may
explain the contradictory results. Overall, these data sug-
gest that PPARβ/δ agonists have anti-inﬂammatory eﬀects
in vivo,b u tn o ts u ﬃcient to inhibit the development
of atherosclerosis in extreme hypercholesterolemic animal
models of the disease. Additional studies will be needed
to determine the exact role of PPARβ/δ in modulating the
development of atherosclerosis can be determined.
8. Concluding Remarks
The treatment and prevention of obesity, insulin resistance,
and type 2 diabetes mellitus requires lifestyle changes,
including weight reduction, increased physical activity and
diet. However, many patients cannot control these patholo-
gies with lifestyle modiﬁcation and there is a need for drugs
to manage them. Activation of PPARβ/δ may become a
pharmacological strategy for treating these disorders. This
treatment improves atherogenic dyslipidemia by reducing
plasma triglyceride levels and enhancing plasma HDL-
cholesterol levels. PPARβ/δ also regulates the availability
of BCL-6, an inﬂammatory suppressor protein that is
released upon ligand binding to PPARβ/δ, thereby behaving
as an “anti-inﬂammatory switch” to control macrophage-
elicited inﬂammation and atherogenesis. In skeletal muscle,
PPARβ/δ ligands may also upregulate fatty acid transport
and oxidation, which reduces fatty acid-induced inﬂamma-
tion and insulin resistance. In adipose tissue, they prevent
the activation of NF-κB by reducing the production of
inﬂammatory cytokines. In addition, PPARβ/δ activation
in the heart prevents cardiac hypertrophy and improves
cardiomyopathy.
As with any drug designed for human therapy, a great
deal of research will be needed on the eﬃcacy and safety
of PPARβ/δ activators before they reach clinical use. For
instance, the ability of PPARβ/δ activators to raise HDL-
cholesterol levels in rodents has been demonstrated in
primates, but the eﬀects of these drugs on the prevention
of obesity in rodents were not observed in primates. This
suggests that weight reduction caused by PPARβ/δ ligands
in mice depends on their eﬀects on thermogenesis, which is
a minor mechanism of energy expenditure in humans and
primates. Safety issues have also been raised regarding the
connection between PPARβ/δ ligands and carcinogenesis,
particularly in animal models [107–110]. However, synthetic
PPARγ and α ligands induce carcinogenesis in rodents,
but do not present these eﬀects in humans [111, 112].
In summary, clinical studies are required to determine the
eﬃcacy and safety of PPARβ/δ ligands.
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